Authors of Systematic Literature Review on Biosimilar Switching Stand by Findings Despite Criticism
May 25th 2018This week, Drugs published a letter to the editor concerning a systematic literature review that showed a low risk of safety concerns or loss of efficacy after switching from a reference biologic product to a biosimilar. The letter’s authors said that switching is a beneficial topic for exploration but criticized the review for “over-interpretation of the available data.”
FDA Releases Educational Video Series on Biosimilars
May 23rd 2018Yesterday, the FDA announced the release of a 5-part video series designed to provide viewers a background of what biosimilar and interchangeable products are, the development and approval process for these products, and the tools and technologies that are used to demonstrate biosimilarity.
High Rate of Inadequate Response to Biologics In Patients Initiating Treatment for RA
May 23rd 2018More than two-thirds of patients with rheumatoid arthritis (RA) previously naïve to biologic disease-modifying anti-rheumatic drugs had an inadequate response to their first biologic during 1 year of follow up, according to a recent Taiwanese study.
No Difference in Quality of Glycemic Control With Biosimilar Versus Originator Insulin
May 22nd 2018An Asian study comparing the quality of glycemic control among patients using biosimilar insulin with those using originator insulin found no independent association of biosimilar insulin with differences in indicators of glycemic control—glycated hemoglobin, insulin dosage, or hypoglycemia.
DAS28 and Mental Health Could Predict Disease Flare in Patients Tapering Anti-TNF Drugs
May 21st 2018Currently, beyond the evaluation of a patient’s 28-joint disease activity score (DAS28), there are no standard methods to determine whether patients will respond well to dose reduction of anti–tumor necrosis factor therapy.
HLA Alleles May Play a Role in Formation of Anti-Drug Antibodies to Adalimumab
May 21st 2018Specific human leukocyte antigen (HLA) alleles are associated with the formation of anti-drug antibodies to adalimumab in patients with rheumatoid arthritis and hidradenitis suppurativa, potentially causing reduced therapeutic response.
ACR Members Push for Legislation on Rising Costs and Barriers to Care
May 19th 2018This week, rheumatologists and rheumatology stakeholders from the American College of Rheumatology (ACR) took to Capitol Hill to advocate on pressing issues in rheumatology care, such as the rising costs of treatment and lack of access to care.
Should Pregnant Patients With Inflammatory Diseases Use Anti-TNF Agents?
May 18th 2018One of the main concerns attributed to anti–tumor necrosis factor (anti-TNF) treatment during pregnancy is the ability for the therapy to be transferred to the fetus. Complete immunoglobulin G (IgG) antibodies, both maternal and therapeutic, are delivered to the placenta during pregnancy naturally. This fact is important for patients who are treated with adalimumab, golimumab, and infliximab, which are complete IgG1 anti-TNF antibodies, and therefore transferred easily to the placenta.
Regulatory Divergence From EMA Would Have Serious Consequences, Says UK Report
May 18th 2018Given reliance on industry fees to pay for the review of medicines, as well as the pharmaceutical industry’s potential inability to sustain the level of fees required to review all new medicines without cooperation with the European Medicines Agency (EMA), the United Kingdom could have to reduce the number of drug marketing authorizations it grants each year, or raise the funds elsewhere.
HHS Seeks Input on "American Patients First" Proposals
May 18th 2018The nature (positive, neutral, or negative) and level of impact of proposals on the biosimilar market will become clearer over time as the President directs HHS to take immediate action on some proposals, and as HHS takes future action, with feedback, on additional proposals.
FDA Names Companies That Restrict Access to Drug Samples for Generic Testing
May 17th 2018Scott Gottlieb, MD, commissioner of the FDA, who has been vocal about "shenanigans" used by innovator drug makers to forestall competition from biosimilars and generics, today announced the publication of a list of companies that have restricted access to samples of small-molecule drugs for testing through the use of Risk Evaluation and Mitigation Strategies programs or limited distribution of their products.
AAPS White Paper Provides Guidance on Analytical Similarity Evaluations of Biosimilars
May 17th 2018The American Association of Pharmaceutical Scientists (AAPS), a professional organization of 9000 scientists, has published a new white paper in The AAPS Journal that discusses the scientific and methodological considerations of the process of attribute and test method selection, criticality assessment, and assignment of analytical measures to the FDA’s 3 tiers of analytical similarity assessment for biosimilars.
CMS Dashboards Show Rising Costs for Drugs Targeted by Biosimilar Competition
May 16th 2018Data from new CMS dashboards reveal that many of the drugs that have seen the highest annual growth in spending per beneficiary over the 2012 to 2016 period are products that either currently face or will soon face biosimilar or follow-on biologic competition.
Study: No New Safety Concerns With Biosimilar Infliximab in Pregnant Patients
May 16th 2018Although the benefits of originator infliximab have been deemed to outweigh the potential harm during pregnancy, in a recent observational study, researchers looked to evaluate whether biosimilar infliximab therapy was associated with any new safety risks.
FDA Approves Pfizer's Epoetin Alfa Biosimilar, Retacrit
May 15th 2018The FDA has approved Pfizer’s biosimilar epoetin alfa, referencing Epogen. The biosimilar, epoetin alfa-epbx, which will be marketed as Retacrit, is the first biosimilar approved in 2018, and the tenth biosimilar to be approved in the United States.
Pfenex Announces Positive Top-Line Results for Proposed Follow-on Teriparatide
May 15th 2018Drug maker Pfenex has announced positive top-line results from a phase 3 study that showed comparable overall profiles between reference teriparatide (Forteo) and Pfenex’s proposed follow-on, PF708, in patients with osteoporosis. Teriparatide, a recombinant human parathyroid hormone, is an anabolic agent that stimulates bone formation.
UK Providers Report Positive Results From Biosimilar Rituximab in Real-World Settings
May 15th 2018At the 58th Annual Scientific Meeting of the British Society for Haematology, held from April 16-18, 2018, in Liverpool, United Kingdom, researchers from 2 hospitals reported on the use of biosimilar rituximab in real-world settings.
Mylan's Insulin Glargine Follow-on Safe and Effective in Treating Type 1 Diabetes
May 14th 2018Mylan’s insulin glargine follow-on, MYL-1501D, referencing Sanofi’s Lantus, is a long-acting human insulin analogue that allows for once-daily basal use in patients with type 1 diabetes. The drug has been authorized for marketing as a biosimilar insulin in the European Union and in Australia under the brand name Semglee.
Does Serum Calprotectin Hold Predictive Value for Clinical Response to Anti-TNF Agents?
May 14th 2018In an effort to accurately predict an individual patient’s response after starting or tapering an anti–tumor necrosis factor (anti-TNF) agent, researchers from the Netherlands, reporting findings in Rheumatic and Musculoskeletal Diseases, explain that calprotectin has some predictive value for clinical response in patients starting anti-TNF treatment, although it was not predictive of clinical response after tapering.
Women With Ankylosing Spondylitis Have Lower Anti-TNF Agent Retention Rate Than Men
May 13th 2018In treating ankylosing spondylitis, anti–tumor necrosis factor (anti-TNF) drugs produce a response in approximately 60% of patients. For the 40% of patients who do not respond to treatment, previous studies have suggested that patient characteristics, including sex, may play a role.
Commonwealth Fund Survey Finds Americans' Concerns Over Healthcare Costs Growing
May 12th 2018This week, the Commonwealth Fund released new findings from its Affordable Care Act Tracking Survey. The survey is a nationally representative telephone poll that tracks coverage rates among 19- to 64-year olds.